Eloralintide: Amylin Receptor Agonist for Advanced Research
Eloralintide (LY 3841136) has recently gained significant attention in peptide research as a promising next-generation amylin receptor agonist (ARA). A peer-reviewed Phase 2 clinical trial randomized 263 adults without type 2 diabetes. At week 48, the published efficacy-estimand analysis reported up to 20% mean body-weight reduction in specified study groups, compared with 0.4% for placebo. Those findings describe the trial medicine, not the properties or safety of separately supplied research material.
What makes eloralintide research worth following now? The program spans standalone amylin agonism, combinations with tirzepatide and registered Phase 3 studies. Those are separate lines of evidence, not a universal result that applies to laboratory reference products. Explore the dated clinical study index and Xcel’s sequence and analytical verification guide for the scientific and material-identity questions.
September 2026 combination update: Lilly reported Phase 2b EloraTZP results in a separate 367-participant study of adults with overweight or obesity and type 2 diabetes. At 48 weeks, the highest reported eloralintide-plus-tirzepatide group had 23.3% mean weight reduction versus 14.8% in the tirzepatide-only group and 3.0% with placebo using the efficacy estimand. These are sponsor-reported combination findings, not a head-to-head comparison with another amylin agonist, and the results do not establish any Xcel research vial’s clinical equivalence.
Understanding Amylin Receptor Agonists
Amylin receptor agonists are synthetic compounds designed to mimic the effects of amylin, a peptide hormone that works in coordination with insulin. In research settings, amylin agonists have demonstrated the ability to slow gastric emptying, regulate post-meal glucose spikes, and enhance satiety signals to the brain in non-human research subjects.
Researchers study amylin-related signaling in different experimental models. Effects depend on the compound, study design and population, and findings for one agent should not be assumed for every member of the class.
Eloralintide’s Mechanism and Research Findings
Eloralintide is a long-acting, selective amylin receptor agonist developed for once-weekly administration. It was designed for long-acting receptor activity. A different molecular design alone does not establish improved tolerability compared with another compound.
A 48-week Phase 2 study by Billings and colleagues randomized 263 adults without type 2 diabetes who had obesity, or overweight with at least one weight-related condition. Study outcomes varied across groups, and nausea and fatigue were among reported adverse events. These clinical findings do not establish the effects or safety of research materials sold by Xcel.
Its pharmacokinetics were evaluated in a Phase 1 study. Results from that studied formulation do not establish the stability, exposure or suitability of a separate research material. For a closer look at analytical identity and sample-specific evidence, see how eloralintide is assessed in the laboratory.
Comparison with Other Amylin Receptor Agonists
| Compound | Classification | Reported Weight Reduction (Research Data) | Administration Profile | Key Notes |
|---|---|---|---|---|
| Pramlintide | Short-acting amylin analog | Varies by study and population | Multiple daily administration | Early amylin analog, limited by short duration |
| Cagrilintide | Long-acting amylin agonist | Varies by study and population | Once-weekly | Long-acting analog investigated in clinical studies |
| Eloralintide | Selective next-generation agonist | About 9–20% mean reduction at 48 weeks across eloralintide groups versus 0.4% with placebo in a Phase 2 study; efficacy estimand | Once-weekly | Selective agonist; comparative tolerability requires direct evidence |
Eloralintide and cagrilintide have different molecular designs. Comparative potency, stability and tolerability cannot be established by this table or by results from separate studies.
Eloralintide Compared with GLP-1 and Multi-Receptor Compounds
Eloralintide preferentially activates certain amylin receptor complexes. Researchers are also studying combinations with incretin compounds; their effects and safety require direct evaluation.
- Semaglutide (GLP-1 agonist): Studied for appetite regulation, glucose control, and weight change. Results vary by study and participant.
- Tirzepatide (GLP-1 + GIP agonist): In the SURMOUNT-1 Phase 3 study, the highest studied group had a 20.9% mean weight reduction at 72 weeks versus 3.1% with placebo in adults without diabetes, using the treatment-regimen estimand.
- Retatrutide (GLP-1 + GIP + glucagon agonist): In a Phase 2 study, the highest studied group had a 24.2% mean weight reduction at 48 weeks versus 2.1% with placebo. These are separate studies with different designs, not a head-to-head comparison.
Explore related research materials: Semaglutide, Tirzepatide, and Retatrutide. Xcel’s separately supplied materials are for laboratory research only and are not the products used in these clinical studies.
Eloralintide’s unique action on the amylin receptor offers a distinct pathway that may complement these compounds. The investigational medicine CagriSema combines cagrilintide with semaglutide in clinical studies. Xcel’s separately supplied cagrilintide and semaglutide research blend is not the clinical trial product; trial findings do not establish the identity, properties or effects of that material.
The Future of Amylin-Focused Research
Eloralintide is being investigated in clinical studies of amylin signaling. In the Phase 3 ENLIGHTEN-6 study, researchers are evaluating eloralintide against placebo in adults with persistent overweight or obesity who are already receiving stable incretin therapy, with or without type 2 diabetes. The study is ongoing, so its results are not yet established. Its development and clinical findings do not establish the safety or effectiveness of research-use materials.
Why the long-acting design attracts interest: In a Phase 1 single-dose study, investigators reported a terminal half-life of approximately 310 to 366 hours across the studied doses. That finding helps explain why researchers are examining a weekly clinical schedule. Our eloralintide half-life guide explains what that measurement does and does not tell us about the investigational compound.
Buy Eloralintide: Next-Generation Amylin Agonist
Explore these resources for more on eloralintide and amylin research.
- What Is Eloralintide?
- How Does Eloralintide Work?
- Understanding Amylin
- Why Long-Acting Amylin Analogues Matter